Citadel Advisors
BCAX

Citadel Advisors’s Bicara Therapeutics BCAX Stock Holding History

Citadel Advisors’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.73M Buy
91,800
+35,100
+62% +$783K ﹤0.01% 5865
2026
Q1 		$1.13M Buy
56,700
+32,100
+130% +$553K ﹤0.01% 7405
2025
Q4 		$414K Buy
+24,600
New +$420K ﹤0.01% 9471

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors's BCAX Position: Q2 2026 in Review

Citadel Advisors reduced its Bicara Therapeutics (BCAX) stake by 87% in Q2 2026, selling an estimated $32.3M and leaving 211,142 shares worth $6.27M. The position accounts for ﹤0.01% of the portfolio, ranked #4332.

Citadel Advisors first reported a position in BCAX in Q3 2024 and has held it in 5 quarters since. The position peaked at $33M in Q1 2026. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Citadel Advisors held 211,142 shares of Bicara Therapeutics worth $6.27M as of Q2 2026.
  • Citadel Advisors sold 1,448,200 Bicara Therapeutics shares in Q2 2026, an estimated $32.3M.
  • Bicara Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #4332 holding.
  • Citadel Advisors first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • Citadel Advisors's Bicara Therapeutics position peaked at $33M in Q1 2026.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.